Oversight Committee
Through project selection and review, and periodic assessment of the program, the Oversight Committee ensures the quality of translational projects and the sustainability of the Translational Partnership. The independent Oversight Committee, chaired by the BME Department Chair, includes members from Duke as well as industry and venture capital.
The roles of the Oversight Committee are:
- Assist with team and proposal solicitation and development
- Review and select individual translational research projects for funding
- Assess periodic reports for the projects and the program
- Evaluate project portfolio
- Provide mentoring to teams
- Provide regular feedback to the Program PI, Co-PI and CPD about the program
- Provide updates to the senior University administration as needed or requested
The committee members include:
- Victoria Christian, Chief Operating Officer, Duke Translational Research Institute
- Craig Henriquez, Ph.D., Chairman and Professor, Department of Biomedical Engineering
- Robert Morff, PhD, Venture Partner
- Barry Myers, M.D., Ph.D., MBA Professor of Biomedical Engineering, Coulter Translational Partnership Grant co-PI, Director of Emerging Programs, Duke Translational Research Institute (DTRI), Ex officio
- Rose Ritts, Ph.D. Executive Director, Office of Licensing and Ventures, Duke University.
- James Rosen, MBA, Intersouth Partners
- Kevin Schulman, Director Professor of Medicine, Duke University School of Medicine, Professor of Business Administration at The Fuqua School of Business, Duke University
- Gregory T. Stelzer, PhD, Independent consultant to specialty pathology companies and in the area of diagnostic assay development, flow cytometry and cell analysis
- John Sundy, M.D., Ph.D., Director, Duke Clinical Research Institute, Associate Professor of Medicine
- Darrel Untereker, Ph.D, Vice President of Research and Technology, Medtronic